Australia · Delayed Price · Currency is AUD Saluda Medical Earnings Call Transcripts
Fiscal Year 2027
-
Q1 revenue grew 26% YoY, while U.S. implants rose 55% to a record 838. FY 2027 guidance was reaffirmed, but cash runway extends only to approximately June 2027 and additional capital will be required.
Fiscal Year 2026
-
Revenue grew 28% year-over-year to $90.2M in FY 2026, with accelerating momentum and strong U.S. performance. FY 2027 guidance targets 25%–35% revenue growth and further gross margin expansion, driven by new product launches and sales force maturation.
-
Revenue grew 28% year-over-year to $90.2 million, exceeding guidance, with Q4 up 43%. FDA approval of the CAP24 paddle lead expands the addressable market by 30%. Cash position and operational efficiency improved, supporting continued growth into FY 2027.
-
Q3 saw 34% year-over-year revenue growth, driven by a 55% increase in U.S. patient implants and strong international performance. FY 2026 revenue guidance was raised to $87 million, with gross margin improvements expected from new product launches and operational efficiencies.
-
Saluda presented its closed-loop spinal cord stimulation technology, highlighting strong clinical outcomes, reduced therapy burden, and significant U.S. market expansion. Financial results show accelerating revenue, improved gross margins, and increased guidance for fiscal 2026.
-
Revenue grew 17% year-over-year to $39.4M in H1 FY26, with gross margin up to 49.4% and strong U.S. and international growth. FY26 revenue guidance reaffirmed at $85M, with improved cash burn and adjusted EBITDA expected.
Fiscal Year 2025
-
Raised AUD 231 million and began ASX trading to fund U.S. commercial expansion. Closed-loop spinal cord stimulation technology offers strong clinical outcomes, low therapy burden, and significant market opportunity, with a focus on rapid sales force growth and new reimbursement models.